Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference | Global News Avenue

modern (messenger RNAThe company’s shares soared further on Friday after a senior executive made upbeat comments at a healthcare conference about the vaccine maker’s product pipeline and cash position.

The Cambridge, Mass.-based company believes its revenue can sustain its business through 2028, Moderna’s head of investor relations Lavina Talukdar said Thursday at the Jefferies London Healthcare Conference.

“We expect to end the year with $9 billion in cash,” Talukdar said, according to a transcript provided by AlphaSense. “Our investment rate…will decline every year going forward. We expect $9 billion to enable us to Launch 10 products in three years that will start contributing to revenue one year after approval.”

Moderna shares were up 7% as recently as Friday afternoon and are up 11% over the past two trading days. Still, Moderna shares are down nearly 60% this year as demand for a COVID-19 vaccine weakens.

Moderna exec downplays possibility of RFK Jr. nominating HHS chief

Talukdar downplays vaccine skeptics’ nomination Robert F. Kennedy Jr. The Department of Health and Human Services (HHS), led by President-elect Donald Trump, has hammered Pharmaceutical companies such as Moderna and Pfizer (PTFE) and Eli Lilly and Company (Li Lai) last Friday.

“If you listen to his recent stance on vaccines, starting in 2022 and up until shortly after the election results came out, he was a lot more moderate than I thought he would be,” she said.

Moderna’s latest third-quarter earnings surprise

Earlier this month, the company sudden profit Third-quarter revenue topped expectations following the rollout of newer COVID-19 vaccines earlier this year.

September, The company said it is launching plans to reduce its size Research and Development (R&D) Budget increases by $1.1 billion over next three years, focusing on Get 10 products Examples include cancer treatments and vaccines for various respiratory diseases that have been approved U.S. Food and Drug Administration (FDA).